Article Search

Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial

January 1, 2026

The PORTEC-4a phase-3 trial showed that using a molecular integrated risk profile to tailor adjuvant therapy after surgery for high-intermediate risk endometrial cancer is safe and effective, and it lets nearly half of patients with favorable profiles avoid any radiation without compromising local control.

Read More »

Nivolumab for Resected Stage III or IV Melanoma 9 Years

January 1, 2026

The 9-year CheckMate 238 data show that adjuvant Nivo maintains a significant recurrent-free survival (RFS) advantage over the International Prognostic Index (Ipi) (median 61.1 vs 24.2 months; 9-year RFS 44% vs 37%) without a statistically significant overall survival (OS) difference (69% vs 65% at 9 years). OS is similar but I think this may highlight the shift towards neoadjuvant immunotherapy (IO) and effective salvage therapies.

Read More »

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

January 1, 2026

The CHRYSALIS-2, the cohort C analysis of patients with atypical EGFR mutations showed meaningful and durable activity. Atypical mutations can be difficult to deal with as a clinician, and having concrete data on these (S768I, L861Q and G719ZX) mutations gives assurance that this doublet is active. Overall response rate (ORR) was 52% and median progression-free survival (PFS) was 11.1 months in refractory patients and 19.5 months in the treatment-naive population.

Read More »

Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial

January 1, 2026

The QUIWI study used quizartinib, a FLT3 drug added to standard chemo induction/consolidation in FLT-negative acute myeloid leukemia (AML) patients. There was a meaningful overall survival (OS) improvement across all age and risk groups including the NPM1+ population. They purposefully used a higher dose to achieve what is felt to be off-target TKI activity in familiar pathways of KIT, PDGRF…etc.

Read More »

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia

January 1, 2026

This is a remarkable proof-of-concept study—11 out of 11 patients with multi-refractory AIHA achieved complete remission after CD19 CART, with rapid Hb normalization and a median drug-free remission of 11.5 months. Toxicity was surprisingly manageable (mostly grade 1–2 cytokine release syndrome (CRS)), and the relapse biology pointing to BCMA+ long-lived plasma cells really sets up a rational next step with plasma cell–directed strategies.

Read More »

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

January 1, 2026

This is a very impressive signal in a notoriously difficult population—seeing a 79% response rate and median progression-free survival (PFS) of 15.4 months in true extramedullary, triple-class–exposed myeloma is better than expected. Toxicity is real and management-intensive, but the depth and durability of response make this dual-bispecific approach feel like a meaningful advance.

Read More »

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

January 1, 2026

This really feels like a first-line practice changer in PD-L1+ MTNBC—the sacituzumab govitecan/pembrolizumab combination delivering a 3.4-month progression-free survival (PFS) improvement and pushing median PFS past 11 months is quite meaningful. Mature overall survival (OS) data will be interesting to see. Remember to watch closely and consider screening for drug-induced interstitial lung disease(ILD).

Read More »

Keyword Search

  • Article Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts